View clinical trials related to Relapsed/Refractory Leukemias.
Filter by:The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.